Application | Comment | Organism |
---|---|---|
medicine | organ simulations indicate that higher therapeutic acetaminophen (0.5 mM) inhibits 16% of allotype ADH1B*1/*1 hepatic ADH activity at 2-20 mM ethanol and that therapeutic salicylate (1.5 mM) inhibits 30-31% of the allotype ADH1B*2/*2 activity, suggesting potential significant inhibitions of ethanol first-pass metabolism in these allelotypes | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
acetaminophen | 0.5 mM, 16% inhibition of hepatic allotype ADH1B*1/*1 activity, 6.1% inhibition of hepatic allotype ADH1B*2/*2 activity | Homo sapiens | |
Acetylsalicylate | 1 mM, 4.4% inhibition of hepatic allotype ADH1B*1/*1 activity, 2.8% inhibition of hepatic allotype ADH1B*2/*2 activity | Homo sapiens | |
cimetidine | 0.2 mM, 2.5% inhibition of hepatic allotype ADH1B*1/*1 activity, 12% inhibition of hepatic allotype ADH1B*2/*2 activity | Homo sapiens | |
salicylate | 1.5 mM, 12% inhibition of hepatic allotype ADH1B*1/*1 activity, 31% inhibition of hepatic allotype ADH1B*2/*2 activity | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|
Synonyms | Comment | Organism |
---|---|---|
ADH1B | - |
Homo sapiens |